Highlights

  • Noxopharm Limited (ASX:NOX) plans to progress SOF-SKN into an extension clinical study involving patients with cutaneous lupus erythematosus.
  • The study is planned to commence in Australia in Q1 CY27 and enrol approximately 15 patients, with initial efficacy signals expected in Q2 CY27.
  • Noxopharm reported an FY26 net loss of AUD 4.46 million, compared with AUD 4.88 million in FY25, while operating cash outflows declined to AUD 2.71 million.
  • At the time of writing this article, Noxopharm Limited (ASX:NOX) was trading at AUD 0.063, up 6.78% during today’s trading session.

At the time of writing this article, Noxopharm Limited (ASX:NOX) was trading at AUD 0.063, up 6.78% during today’s trading session. Noxopharm is an Australian clinical-stage biotechnology company developing targeted therapies for chronic inflammation, autoimmune diseases and cancer. Its development activities are centred on the Sofra technology platform, including lead clinical asset SOF-SKN, alongside oncology programs. Recent developments have focused on advancing SOF-SKN beyond its first-in-human study, while FY26 results highlighted lower operating cash outflows and continued expenditure on drug development.

Company Business

Noxopharm develops proprietary drug candidates through two technology platforms: Sofra and Chroma. Sofra is based on synthetic nucleic acids known as oligonucleotides and is designed to regulate innate immune signalling. The platform is being developed across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

SOF-SKN is the company’s lead clinical asset and is being developed as a topical treatment for cutaneous lupus erythematosus, or CLE. Noxopharm completed the Phase I HERACLES study in healthy volunteers during FY26, evaluating SOF-SKN at four concentrations. The company reported no relevant safety issues from the study.

The Chroma platform is focused primarily on oncology and includes preclinical drug candidates being investigated across different cancer applications. Noxopharm also works with external research and commercial collaborators to evaluate compounds originating from its technology platforms.

Recent Development

In September 2026, Noxopharm outlined the next stage of clinical development for SOF-SKN. The company plans to commence an extension clinical study in CLE patients in Melbourne during Q1 CY27, subject to regulatory, contractual and ethics requirements.

Approximately 15 patients are expected to be enrolled. Each patient is planned to receive topical SOF-SKN once daily for 14 days, followed by a seven-day follow-up period. The study will assess safety and tolerability while also examining initial signals of clinical efficacy.

Noxopharm expects patient recruitment, treatment and initial efficacy reporting to occur during Q2 CY27. A broader clinical data readout covering efficacy signals, safety and tolerability is anticipated in Q4 CY27.

Data from the extension study is intended to help inform the design of a planned Phase II CLE trial, which the company is targeting for the first half of CY28, subject to regulatory feedback and other clinical and Manufacturing requirements.

Noxopharm has also been progressing its US regulatory strategy. During FY26, it engaged a clinical research organisation as part of preparations for a pre-Investigational New Drug meeting with the US Food and Drug Administration.

Financial Performance and Sector Context

For the year ended 30 June 2026, Noxopharm reported a net loss after tax of AUD 4.46 million, compared with AUD 4.88 million in FY25, representing an 8.8% reduction.

Other income was AUD 1.45 million, down from AUD 2.83 million in FY25. The result included AUD 1.43 million from Research and Development tax incentives.

Research and development expenses declined to AUD 1.94 million from AUD 4.27 million in the previous year, while consulting, employee and director expenses decreased to AUD 2.10 million from AUD 3.00 million. Finance costs increased to AUD 1.16 million from AUD 0.50 million.

Net cash used in Operating Activities was AUD 2.71 million in FY26, compared with AUD 5.82 million in FY25. Cash and cash equivalents stood at AUD 0.29 million at 30 June 2026, compared with AUD 1.55 million a year earlier.

The company also had AUD 4.37 million in convertible note liabilities at year-end and an outstanding Unsecured Loan balance of approximately AUD 0.20 million.

Clinical-stage biotechnology companies typically require ongoing funding while progressing candidates through development and regulatory processes. For Noxopharm, future funding requirements, clinical execution and regulatory progression remain closely connected to the development timetable for SOF-SKN and other pipeline assets.

Risks to Consider

Noxopharm remains exposed to clinical development risk, including the possibility that future studies may not demonstrate sufficient efficacy, safety or tolerability to support further development.

The company also faces regulatory, manufacturing and clinical trial execution risks, including delays in approvals, recruitment or trial commencement. Its cash position and reliance on external funding are additional considerations, particularly while the Business remains pre-commercial and continues to record operating losses.

Convertible notes and other financing arrangements also create balance-sheet obligations that need to be monitored alongside future Capital requirements.

What to Watch Next

The planned commencement of the SOF-SKN CLE extension study in Q1 CY27 is a key upcoming milestone. Patient recruitment and initial efficacy signals expected during Q2 CY27 will provide further information on the clinical development program.

Investors may also monitor the full study readout anticipated in Q4 CY27, progress toward the planned Phase II trial, US regulatory interactions and updates from the broader Sofra and Chroma development pipelines.

Cash expenditure, funding initiatives and changes in the company’s Balance Sheet will remain important financial indicators as clinical programs progress.

Key Insights

Noxopharm is moving SOF-SKN from an initial Phase I study in healthy volunteers toward clinical testing in patients with cutaneous lupus erythematosus. The planned extension study represents the next stage in assessing the therapy’s safety, tolerability and potential efficacy in the target patient population.

FY26 financial results showed a lower net loss and reduced operating cash outflows compared with FY25, although the company finished the year with a limited cash balance and ongoing financing obligations. Clinical execution, study data, regulatory progress and funding remain the principal factors to monitor.